RxDoctor Payments Data

Ira Perszyk, MD

Ophthalmology · Bellingham, WANPI 1508278268

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,654 of the $17,482 with a category attached, or 78.1%. 23 manufacturers reported payments, led by AbbVie at 31.4% of the total. Reporting peaked in 2024 at $3,934 and has fallen 65.3% since, to $1,366 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,482in general payments, 2019–2025

Across 270 payments — averaging $64.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Sight Sciences, Inc.$3K
  • Ivantis, Inc$2K
  • Alcon$2K
  • Glaukos Corporation$2K
  • Sun Pharmaceutical Industries Inc.$972
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$1,5009%
  • Travel & lodging$2,23013%
  • Food & beverage$13,65478%
  • Education$981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,482 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$288,325
Medicare patients
771
Services billed
2,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost94$35,488
RocklatanNetarsudil Mesylat/Latanoprost43$28,008
VyzultaLatanoprostene Bunod43$23,970
RestasisCyclosporine15$20,906
XiidraLifitegrast20$19,233
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol67$16,342
CombiganBrimonidine Tartrate/Timolol39$16,105
RhopressaNetarsudil Mesylate32$15,372
Prednisolone Acetate320$14,753
ProlensaBromfenac Sodium31$10,458
Alphagan PBrimonidine Tartrate19$9,217
Latanoprost616$9,021
SimbrinzaBrinzolamide/Brimonidine Tart25$8,302
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat431$7,567
Brimonidine Tartrate226$7,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$5,488$81,716167 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$264$43,38075 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$291$43,20363 claims
AlconSimbrinza, Azopt$2,076$12,62337 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$137$12,43443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →